Chest
Volume 133, Issue 6, Supplement, June 2008, Pages 708S-775S
Journal home page for Chest

Supplement
Antithrombotic and Thrombolytic Therapy 8th ED: ACCP Guidelines
Acute ST-Segment Elevation Myocardial Infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)

https://doi.org/10.1378/chest.08-0665Get rights and content

This chapter about fibrinolytic, antiplatelet, and antithrombin treatment for acute ST-segment elevation (STE) myocardial infarction (MI) is part of the American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Grade 1 recommendations are strong and indicate that the benefits do, or do not, outweigh risks, burden, and costs. Grade 2 suggests that individual patient values may lead to different choices (for a full understanding of the grading see the chapter by Guyatt et al, CHEST 2008; 133[suppl]:123S–131S). Among the key recommendations in this chapter are the following: for patients with ischemic symptoms characteristic of acute MI of ≤ 12 h in duration and persistent STE, we recommend that all undergo rapid evaluation for reperfusion (primary percutaneous coronary intervention [PCI] or fibrinolytic) therapy and have a reperfusion strategy implemented promptly after contact with the health-care system (Grade 1A). For patients with ischemic symptoms characteristic of acute MI of ≤ 12 h in duration and persistent STE, we recommend administration of streptokinase, anistreplase, alteplase, reteplase, or tenecteplase over no fibrinolytic therapy (all Grade 1A). For patients with symptom duration ≤ 6 h, we recommend the administration of alteplase or tenecteplase over streptokinase (both Grade 1A). We recommend aspirin over no aspirin therapy followed by indefinite therapy (Grade 1A); we also recommend clopidogrel in addition to aspirin for up to 28 days (Grade 1A). In addition to aspirin and other antiplatelet therapies, we recommend the use of antithrombin therapy (eg, unfractionated heparin (UFH), enoxaparin, or fondaparinux) over no antithrombin therapy (Grade 1A), including for those patients receiving fibrinolysis (and regardless of which lytic agent is administered), primary PCI, or patients not receiving reperfusion therapy.

Section snippets

Reperfusion Therapy

1.0.1. For patients with ischemic symptoms characteristic of acute MI of ≤ 12 h duration and persistent STE, we recommend that all undergo rapid evaluation for reperfusion (primary PCI or fibrinolytic) therapy and have a reperfusion strategy implemented promptly after contact with the health-care system (Grade 1A).

Fibrinolysis

1.1.1. In patients with acute MI who are candidates for fibrinolytic therapy, we recommend administration as soon as possible (ideally within 30 min) after arrival to the hospital or

References (271)

  • A Roth et al.

    Should thrombolytic therapy be administered in the mobile intensive care unit in patients with evolving myocardial infarction? A pilot study

    J Am Coll Cardiol

    (1990)
  • J Schofer et al.

    Prehospital thrombolysis in acute myocardial infarction

    Am J Cardiol

    (1990)
  • L Karagounis et al.

    Impact of field-transmitted electrocardiography on time to in-hospital thrombolytic therapy in acute myocardial infarction

    Am J Cardiol

    (1990)
  • E Bonnefoy et al.

    Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study

    Lancet

    (2002)
  • J Rawles

    Halving of mortality at 1 year by domiciliary thrombolysis in the Grampian Region Early Anistreplase Trial (GREAT)

    J Am Coll Cardiol

    (1994)
  • DA Morrow et al.

    Evaluation of the time saved byprehospital initiation of reteplase for ST-elevation myocardial infarction: results of the early retavase-thrombolysisin myocardial infarction (ER-TIMI) 19 trial

    J Am Coll Cardiol

    (2002)
  • E Boersma et al.

    Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour

    Lancet

    (1996)
  • CP Cannon et al.

    The electrocardiogram predicts one-year outcome of patients with unstable angina and non-Q wave myocardial infarction: results of the TIMI III registry ECG ancillary study

    J Am Coll Cardiol

    (1997)
  • CK Wong et al.

    Patients with prolonged ischemic chest pain and presumed-new left bundle branch block have heterogeneous outcomes depending on the presence of ST-segment changes

    J Am Coll Cardiol

    (2005)
  • BL Huey et al.

    A comprehensive analysis of myocardial infarction due to left circumflex artery occlusion: comparison with infarction due to right coronary artery and left anterior descending artery occlusion

    J Am Coll Cardiol

    (1988)
  • S Matetzky et al.

    Significance of ST segment elevations in posterior chest leads (V7 to V9) in patients with acute inferior myocardial infarction: application for thrombolytic therapy

    J Am Coll Cardiol

    (1998)
  • MD Cheitlin et al.

    ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (ACC/AHA/ASE committee to update the 1997 guidelines for the clinical application of echocardiography)

    J Am Coll Cardiol

    (2003)
  • ML Simoons et al.

    Individual risk assessment for intracranial haemorrhage during thrombolytic therapy

    Lancet

    (1993)
  • RP Giugliano et al.

    Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage

    Am Heart J

    (2001)
  • V Menon et al.

    New heparin dosing recommendations for patients with acute coronary syndromes

    Am J Med

    (2001)
  • H Wienbergen et al.

    Incidence, risk factors, and clinical outcome of stroke after acute myocardial infarction in clinical practice

    Am J Cardiol

    (2001)
  • T Huynh et al.

    Predictors of intracranial hemorrhage with fibrinolytic therapy in unselected community patients: a report from the FASTRAK II project

    Am Heart J

    (2004)
  • CB Granger et al.

    A pooled analysis of coronary arterial patency and left ventricular function after intravenous thrombolysis for acute myocardial infarction

    Am J Cardiol

    (1994)
  • KL Neuhaus et al.

    Improved thrombolysis with a modified dose regiment of recombinant tissue-type plasminogen activator

    J Am Coll Cardiol

    (1989)
  • RJ Carney et al.

    Randomized angiographic trial of recombinant tissue-type plasminogen activator (alteplase) in myocardial infarction: rAAMI Study Investigators

    J Am Coll Cardiol

    (1992)
  • KL Neuhaus et al.

    Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: results of the rt-PA-APSAC patency study (TAPS)

    J Am Coll Cardiol

    (1992)
  • CP Cannon et al.

    Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial

    J Am Coll Cardiol

    (1994)
  • Lancet

    (1988)
  • G De Luca et al.

    Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts

    Circulation

    (2004)
  • DO Williams

    Treatment delayed is treatment denied

    Circulation

    (2004)
  • EM Antman et al.

    ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction)

  • WD Weaver et al.

    Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review

    JAMA

    (1997)
  • Am Heart J

    (2003)
  • F Zijlstra et al.

    A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction

    N Engl J Med

    (1993)
  • CL Grines et al.

    A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction

    N Engl J Med

    (1993)
  • RJ Gibbons et al.

    Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction

    N Engl J Med

    (1993)
  • CL Grines et al.

    Coronary angioplasty with or without stent implantation for acute myocardial infarction

    N Engl J Med

    (1999)
  • GW Stone et al.

    Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction

    N Engl J Med

    (2002)
  • F Zijlstra et al.

    Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction

    N Engl J Med

    (1999)
  • F Bednar et al.

    Interhospital transport for primary angioplasty improves the long-term outcome of acute myocardial infarction compared with immediate thrombolysis in the nearest hospital (one-year follow-up of the PRAGUE-1 study)

    Can J Cardiol

    (2003)
  • E Boersma

    The Primary Coronary Angioplasty vs Thrombolysis (PCAT)-2 Trialists' Collaborative Group. Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients

    Eur Heart J

    (2006)
  • BK Nallamothu et al.

    Times to treatment in transfer patients undergoing primary percutaneous coronary intervention in the United States: National Registry of Myocardial Infarction (NRMI)-3/4 analysis

    Circulation

    (2005)
  • JG Canto et al.

    The volume of primary angioplasty procedures and survival after acute myocardial infarction

    N Engl J Med

    (2000)
  • DJ Magid et al.

    Relation between hospital primary angioplasty volume and mortality for patients with acute mi treated with primary angioplasty vs thrombolytic therapy

    JAMA

    (2000)
  • M Grzybowski et al.

    Mortality benefit of immediate revascularization of acute ST-segment elevation myocardial infarction in patients with contraindications to thrombolytic therapy: a propensity analysis

    JAMA

    (2003)
  • Cited by (0)

    Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal.org/misc/reprints.shtml).

    View full text